GlassScriptPhysician profile
Sara Capatanos
NPI 1558524322
$1,381.52
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $319 · 2022: $211.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $239.70 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $225.43 | 2019-2022 | |
| Astellas Pharma US INC | $134.72 | 2019-2022 | |
| Genzyme Corporation | $76.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $73.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $71.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $69.29 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.37 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $50.80 | 2019 | |
| Seagen INC. | $48.61 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $47.98 | 2019 | |
| Pfizer INC. | $43.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.71 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $31.59 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $24.69 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $24.29 | 2019 | |
| Agios Pharmaceuticals, INC. | $23.70 | 2019 | |
| Genentech USA, INC. | $21.70 | 2019 | |
| Puma Biotechnology, INC. | $20.82 | 2019 | |
| Incyte Corporation | $18.64 | 2019 | |
| Gilead Sciences, INC. | $14.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.60 | 2020 | |
| Rigel Pharmaceuticals, INC. | $14.54 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Capatanos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.